Guest Post: Pharmacists EMiT Care for Transplant Patients
Read the guest post by clinical pharmacist Winnie Ma about her Hacking Health experience.
ReadLinks Guest Posts
ReadLinks Guest Posts are intended to expose the public and pharmacy professionals to a diverse range of knowledge, and expertise, with the goal of expanding awareness of issues related to public safety and pharmacy practice. While the College enforces strict Guest Post Submission Guidelines, the views and opinions expressed in these articles are those of the author(s) and do not necessarily reflect the official standards or positions of the College of Pharmacists of British Columbia.
Guest Post: Join Pharmacists to Study Mobile Health and Asthma Medication Adherence
Read the Guest Post by Dr. Mary De Vera and Natasha Campbell of the UBC Faculty of Pharmaceutical Sciences.
Guest Post: Comparative effectiveness of proton pump inhibitors
In six previous Therapeutics Letters, we reported information about the benefits and harms of different proton pump inhibitors (PPIs).These drugs work by irreversibly inhibiting gastric H+K+ ATPase (the proton pump) in the stomach. They inhibit both basal and stimulated acid secretion and are used in a number of clinical settings: gastroesophageal reflux disease (GERD), reflux esophagitis, peptic ulcer disease (PUD), and symptoms associated with stomach acid such as heartburn and acid indigestion.
Guest Post: Whistler Gets The Mumps!
Read the guest post by consultant pharmacist Jennifer Dunkin and community pharmacist Lexi Shewchuk.
Guest Post: Pharmacists’ Care of People at Risk of Suicide Survey
Read the guest post from Dr. David Gardner and Dr. Andrea Murphy from Dalhousie University.
Guest Post: UBC Pharmacy Residents Spend a Week at the College
Read the guest post from UBC Pharmacy Residents Andrea Silver and Andrew Cobleigh.
Guest Post: Part-Time Pharmacist Facilitators Needed at UBC
Read the guest post from Clinical Pharmacist and UBC Lecturer Vaughn Chauvin.
Guest Post: Benefits and harms of drugs for “neuropathic” pain
Drugs like gabapentin, pregabalin, duloxetine, venlafaxine, and tricyclic antidepressants are often used to treat neuropathic pain. In fact, in the last decade, use of these drugs has steadily increased in BC residents with total spending approximately >$50 million per year.
How often do these drugs provide meaningful reductions in pain and at what doses? How soon can you tell if the drugs are helping reduce pain? How often will patients suffer harm from these drugs? Is there a practical strategy for using these drugs in patients with neuropathic pain based on the best available evidence?